A dynamic interaction between CD19 and the tetraspanin CD81 controls B cell co-receptor trafficking

  1. Katherine J Susa
  2. Tom CM Seegar
  3. Stephen C Blacklow  Is a corresponding author
  4. Andrew C Kruse  Is a corresponding author
  1. Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, United States
  2. Dana Farber Cancer Institute, Department of Cancer Biology, United States
5 figures, 2 tables and 1 additional file

Figures

Figure 1 with 2 supplements
CD81 chimera design and CD19 Export Assay.

(A) Design of CD81 Chimeras used in export assay experiments. (B) Export assay with CD81/CD9 chimeras. (C) Export assay with CD81/Tspan15 C. elegans chimeras. (D) Export assay with CD19/ σ1 receptor transmembrane domain chimera. (E) Export assay with a secreted construct of the CD81 large extracellular loop. For the data in panels (B – E), surface CD19 was detected by flow cytometry using an Alexa 488-coupled anti-CD19 antibody. Each figure represents three independent experiments. Error bars represent mean ± SEM. Statistical analysis was performed in GraphPad Prism using an unpaired two-tailed t test. **p<0.01; ***p<0.001, ****p<0.0001.

Figure 1—figure supplement 1
Surface staining of CD81 chimeras used in the CD19 Export Assay.

Expression was analyzed using an anti-CD81 antibody, so only chimeras with the large extracellular loop of CD81 are detectable. (A) CD81 surface staining of parental HEK293T cells compared to CRISPR knockout cells. (B) Panel of CD81 chimeras used in export assay. (C) CD81 surface staining of CD9/CD81 chimeras detected with 5A6 antibody. (D) CD81 surface staining of CD81/Tspan15 C. elegans chimeras detected with 5A6 antibody. Error bars represent mean ± SEM of three independent experiments.

Figure 1—figure supplement 2
Representative gating strategy for CD81 null 293 T cells used in the CD19 export assay and CD19-CD81 fusion protein validation experiments.

Cells were first gated on live cells and then on singlet cells.

Figure 2 with 1 supplement
Design and evaluation of a CD19-CD81 fusion protein.

(A) Cartoon representing the designed CD19-CD81 fusion protein. The model was created based on known structures of the CD19 ectodomain (PDB 6AL5) and CD81 (PDB 5TCX). A short Gly-Ser linker (dashed lines) connects P329 of the intracellular portion of CD19 to the N-terminus of CD81. (B) Analysis of CD19 surface staining in CD81-null cells expressing the CD19-CD81 fusion protein. Surface staining for the CD19-CD81 fusion is compared to staining of cells expressing only CD19, and to staining of cells expressing both CD19 and CD81, using an Alexa 488-coupled anti-CD19 antibody. (C) Binding of various CD81 antibodies to the CD19-CD81 complex, analyzed by flow cytometry. ‘Fraction maximum binding’ was calculated by dividing the average MFI of antibody bound to CD19-CD81 by the average MFI of antibody bound to CD81. An anti-human IgG-Alexa 488 secondary antibody was used to detect CD81 antibody bound to the cell surface. For the data in panel B and C, each figure represents three independent experiments and error bars represent mean ± SEM. Statistical analysis was performed in GraphPad Prism using an unpaired t test. **p<0.01; ***p<0.001, ****p<0.0001.

Figure 2—figure supplement 1
Validation of the CD19-CD81 fusion protein with a panel of CD19 antibodies.

A panel of CD19 antibodies recognizes the CD19-CD81 fusion to the same degree as it recognizes wild type CD19, providing further evidence that the fusion protein is properly folded. Error bars represent mean ± SEM of three independent experiments.

Figure 3 with 3 supplements
Structure of the 5A6 Fab-CD81 Large Extracellular Loop Complex (PDB 6U9S).

(A) Surface representation of the 5A6-CD81 complex. CD81 is blue, the 5A6 Fab light chain is yellow, and the heavy chain is magenta. Residues at the binding interface are colored in a darker shade. (B) CD81 colored by evolutionary conservation score using the top 50 CD81-related sequences determined by Consurf (Landau et al., 2005).(C) 5A6 Fab-CD81 binding interface. Heavy chain (left panel) and light chain (right panel) contacts are shown. Hydrogen bonding interactions are indicated with dotted lines. (D) Structural superposition of 5A6 bound CD81 on full length CD81. Arrows indicate positional shifts of the variable helices C and D in the 5A6-bound structure. (E) CD19 Export Assay with Helix C and D Mutants. Surface CD19 was detected by flow cytometry using an Alexa 488-coupled anti-CD19 antibody. Expression of helix C and D mutants was confirmed by flow cytometry (Figure 3—figure supplement 3). For the data in panel E, error bars represent mean ± SEM of three independent experiments. Statistical analysis was performed in GraphPad Prism using an unpaired t test. **p<0.01; ***p<0.001, ****p<0.0001.

Figure 3—figure supplement 1
Representative Density in the CDRs of 5A6 Fab.

(A–B) Composite omit 2Fo-Fc electron density map contoured at 1.0 σ for CD81 Helix C (A) and CD81 Helix D (B).

Figure 3—figure supplement 2
Epitope comparison of Ab5, Ab10, Ab21, and 5A6.

(A) Surface representation of CD81 large extracellular loop colored purple for residues within 4 Å of Ab21 (PDB 5DFW). (B) Surface representation of CD81 large extracellular loop colored red for residues within 4 Å of Ab10 (PDB 6EK2). (C) Surface representation of CD81 large extracellular loop colored green for residues within 4 Å of Ab5 (PDB 6EJM). (D) Surface representation of CD81 large extracellular loop colored blue for residues within 4 Å of 5A6. (E) Superposition of Ab21 and 5A6 complexes, comparing binding sites and angles of approach for Ab21 and 5A6. (F) Superposition of Ab5 and 5A6 complexes, comparing binding sites and angles of approach for Ab5 and 5A6. (G) Superposition of Ab10 and 5A6 complexes, comparing binding sites and angles of approach for Ab10 and 5A6.

Figure 3—figure supplement 3
CD81 surface staining of polyalanine mutants detected with Ab21.

Error bars represent mean ± SEM of three independent experiments.

Figure 4 with 2 supplements
CD81 antibody labeling experiments in resting and activated primary human B cells.

(A) Surface staining of the B cell activation markers, CD86 and CD69, in resting B cells and cells activated with IgM, IgG Fab’2. (B) Surface staining of CD19 and CD81 with antibody 5A6 and Ab21. (C) Percent of CD81 positive cells labeled with 5A6 or Ab21. (D) Western blots of total protein lysate. ‘R’ represents resting cells and ‘A’ represents activated cells. (E) Immunopurification of CD19 from resting and activated primary human B cells, followed by western blotting for CD19, and for CD81 using Ab21. ‘R’ represents resting cells and ‘A’ represents activated cells. (F) Densitometry analysis of western blots of whole cell lysates shown in Panel D. (G) Densitometry analysis of western blots of CD19-CD81 co-immunoprecipitation shown in Panel E. For all panels, data are shown as mean ± SEM. Three replicates were performed for CD81 5A6 and Ab21 staining, and two replicates were performed for CD19, CD69, and CD86 staining conditions. Statistical analysis was performed in GraphPad Prism using an unpaired t test. **p<0.01; ***p<0.001, ****p<0.0001.

Figure 4—figure supplement 1
Replicate western blots.

(A) Replicate western blots of total protein lysate from Figure 4D. ‘R’ represents resting cells and ‘A’ represents activated cells. (B) Replicate immunoprecipitations of CD19 from resting and activated primary human B cells, followed by western blotting for CD19, and for CD81 using Ab21. ‘R’ represents resting cells and ‘A’ represents activated cells.

Figure 4—figure supplement 2
Representative gating strategy for primary human B cells.

Cells were first gated on live cells, then on singlet cells, and then on CD20+ cells.

Proposed model for the disengagement of the CD81 during B cell activation.

Upon B cell activation, dissociation of the B cell co-receptor complex could allow CD19 to freely diffuse in the membrane and interact with the BCR, leading to amplified signaling through the BCR and activation of the B cell.

Tables

Table 1
X-ray crystallography data collection and refinement statistics.

Refined coordinates and structure factors are deposited in the Protein Data Bank under accession code 6U9S.

Data collection5A6-CD81 LEL
Wavelength (Å)0.9792
Space GroupP 21 21 21
Number of crystals1
Unit cell dimensions
a,b,c40.003, 96.858, 297.091
α, β, γ (°)90, 90, 90
Resolution (Å) (last shell)49.5–2.4 (2.54–2.4)
No. of reflections (total/unique)293920/46497
Completeness (%) (last shell)99.1 (96.8)
I/σ(I) (last shell)7.94 (0.46)
Rmeas (%) (last shell)20.5% (355.7%)
CC1/2 (%) (last shell)99.5 (16.6)
Multiplicity6.3
Refinement
Number of atoms (protein/solvent)7974/358
Rwork/Rfree (%)21.44/28.08
R.M.S. deviation (Å)
Bond length0.003
Bond angles0.537
Ramachandran statistics
Favored96.94
Allowed3.06
Outliers0.00
Key resources table
Reagent type
(species) or
resource
DesignationSource or
reference
IdentifiersAdditional
information
AntibodyRabbit Polyclonal CD19 antibodyCell SignalingCat#3574S; RRID:AB_22755231:500 (western blot)
AntibodyCD19 Mouse Monoclonal Antibody (SJ25-C1), Alexa Fluor 488Thermo-FisherCat#MHCD1920; RRID:AB_3893132 µg/mL (flow cytometry)
AntibodyGAPDH (D16H11) Rabbit Monoclonal Antibody (HRP Conjugate)Cell SignalingCat#8884S; RRID:AB_111298651:10,000 (western blot)
AntibodyAPC Mouse Monoclonal anti-human CD81BioLegendCat#349510; RRID:AB_25640202 µg/mL (flow cytometry)
AntibodyHuman Monoclonal CD81 Clone Ab5Recombinant; Nelson et al., 20182 µg/mL (flow cytometry)
AntibodyHuman Monoclonal CD81 Clone Ab10Recombinant; Nelson et al., 20182 µg/mL (flow cytometry)
AntibodyHuman Monoclonal CD81 Clone Ab21Recombinant; Nelson et al., 20182 µg/mL (flow cytometry) 1:1000 (western blot)
AntibodyHuman Monoclonal CD81 Clone 5A6Recombinant; WO 2017/218691 A12 µg/mL (flow cytometry) 1:100 (western blot)
AntibodyHuman Monoclonal
CD19 (Coltuximab)
Recombinant; Therapeutic Antibody Database2 µg/mL (flow cytometry)
AntibodyHuman Monoclonal CD19 (Denintuzumab)Recombinant; Therapeutic Antibody Database2 µg/mL (flow cytometry)
AntibodyHuman Monoclonal CD19 (Inebiliziumab)Recombinant; Therapeutic Antibody Database2 µg/mL (flow cytometry)
AntibodyAPC Mouse Monoclonal CD86 antibodyBioLegendCat#374208; RRID:AB_27214492 µg/mL (flow cytometry)
AntibodyAPC Mouse Monoclonal CD20 Clone L27BD BiosciencesCat#340941; RRID:AB_16457241 µg/mL (flow cytometry)
AntibodyDonkey anti-Rabbit IgG (H+L) HRP ConjugateSigma AldrichCat#GENA934-1ML; RRID:AB_27226591:5000 (western blot)
AntibodyRabbit Anti-Human IgG H and L HRP ConjugateAbcamCat#ab6759; RRID_:AB_9554341:5000 (western blot)
AntibodyF(ab')2-Goat anti-Human IgG, IgM (H+L), Functional GradeThermo-FisherCat#16-5099-8520 µg/mL (B cell activation)
Biological sample (human)Leuko-reduction CollarBrigham and Women’s Hospital Crimson Core
Commercial assay or kitQuickExtract DNA Extraction SolutionVWRCat#76081–766
Chemical compoundValproic Acid Sodium SaltSigma AldrichCat#P4543-25G
Chemical compound, drugD-(+)-Glucose solutionSigma AldrichCat#G8769-100ML
Chemical compound, drugMagnesium Formate DiHydrateHampton ResearchCat#HR2-537
Chemical compound, drugStockOptions Sodium AcetateHampton ResearchCat#HR2-933-01
Chemical compound, drugPolyethylene Glycol Monomethyl Ether 550Hampton ResearchCat#HR2-611
OtherMicroToolsHampton ResearchCat#HR4-837
Commercial assay or kitRosetteSep Human B Cell Enrichment CocktailSTEMCELL TechnologiesCat#15024
Commercial assay or kitLymphoprep density gradient mediumSTEMCELL TechnologiesCat#07851
Chemical compound, drugNutridoma-SPSigma AldrichCat#11011375001
Chemical compound, drugn-Dodecyl-B-D-maltoside (DDM)AnatraceCat#D310
Chemical compound, drugCholesteryl HemisuccinateSigma AldrichCat#C6512
Chemical compound, drugIodoacetamideSigma AldrichCat# I1149-5G
Peptide, recombinant proteinBenzonase nucleaseSigma AldrichCat# E1014-25KU
Commercial assay or kitIn-Fusion HD Cloning PlusClontechCat# 638911
Cell line (human)Expi293F CellsThermo-FisherCat#A14527
Cell line (human)CD81 null HEK293T cellsThis paperHEK293T cells with CD81 knocked out using CRISPR/Cas9
Sequence-based reagentgRNA forward primer for CD81 knockout cell line generationIntegrated DNA TechnologiesCACCGATGCGCTGCGTCTGCGGCG
Sequence-based reagentgRNA reverse primer for CD81 knockout cell line generationIntegrated DNA TechnologiesAAACCGCCGCAGACGCAGCGCATC
Recombinant DNA reagentpcDNA3.1 (+) Mammalian Expression VectorThermo-FisherCat#V79020
Recombinant DNA reagentpFUSE-hIgG1-Fc2InvivoGenCat#pfuse-hg1fc2
Recombinant DNA reagentpD2610-v5 CMV(v5)-ORF Mamm-ElecDATUMN/A
Recombinant DNA reagentgBlocksIntegrated DNA TechnologiesN/A
Recombinant DNA reagentpSpCas9(BB)−2A-GFP (PX458)AddgeneCat#48138
Software, algorithmGraphPad Prism 8.0N/Ahttp://www.graphpad.com/scientific-software/prism/
Software, algorithmBD Accuri C6 Plus softwareBD Accuri C6 Plushttp://www.bdbiosciences.com/en-us/instruments/research-instruments/research-cell-analyzers/accuri-c6-plus
Software, algorithmSB Grid ConsortiumMorin et al., 2013https://sbgrid.org/software/
Software, algorithmXDSKabsch, 2010https://sbgrid.org/software/
Software, algorithmPhenixAfonine et al., 2012https://sbgrid.org/software/
Software, algorithmCootEmsley and Cowtan, 2004https://sbgrid.org/software/
Software, algorithmPyMOLDeLano, 2010https://sbgrid.org/software/

Additional files

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Katherine J Susa
  2. Tom CM Seegar
  3. Stephen C Blacklow
  4. Andrew C Kruse
(2020)
A dynamic interaction between CD19 and the tetraspanin CD81 controls B cell co-receptor trafficking
eLife 9:e52337.
https://doi.org/10.7554/eLife.52337